Construction of a nomogram model to predict the risk of retinopathy of prematurity reactivate after intravitreal anti-vascular endothelial growth factor therapy: a retrospective study

被引:0
|
作者
Shen, Ziyun [1 ]
Hao, Qingfei [1 ]
Yang, Tiantian [1 ]
Cheng, Xiuyong [1 ]
机构
[1] Zheng Zhou Univ, Affiliated Hosp 1, Dept Neonatol, Zhengzhou, Peoples R China
来源
FRONTIERS IN PEDIATRICS | 2025年 / 12卷
关键词
anti-vascular endothelial growth factor; retinopathy of prematurity; reactivate; nomogram; preterm; BLOOD-TRANSFUSION; BEVACIZUMAB; MANAGEMENT; INFANTS;
D O I
10.3389/fped.2024.1440437
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective To explore the risk factors for the reactivate of retinopathy of prematurity (ROP) after intravitreal injection of anti-vascular endothelial growth factor (VEGF) and to construct a nomogram model to predict the risk of ROP reactivate. Methods A retrospective analysis was conducted on 185 ROP children who underwent anti-VEGF treatment at the First Affiliated Hospital of Zhengzhou University from January 2017 to October 2023. They were randomly divided into a training set (129 cases) and a validation set (56 cases) at a ratio of 7:3. The training set was further divided into a reactivate group (n = 18) and a non-reactivate group (n = 111) based on whether ROP recurred after treatment. Multivariable logistic regression analysis was used to screen for risk factors for ROP reactivate. A nomogram model was constructed using R software and validated using the validation set. The discrimination, calibration, and clinical net benefit of the model were evaluated using the receiver operating characteristic curve (ROC curve), calibration curve, and decision curve analysis, respectively. Results Multivariable logistic regression analysis showed that the number of red blood cell transfusions, use of pulmonary surfactant (PS) 2 times or more, and preoperative fundus hemorrhage were independent risk factors for ROP reactivate (P < 0.05). The area under the ROC curve (AUC) of the training set was 0.810 (95% CI: 0.706-0.914), and that of the validation set was 0.756 (95% CI: 0.639-0.873). The Hosmer-Leme show goodness-of-fit test indicated a good fit of the model (P = 0.31). Calibration curve analysis and decision curve analysis suggested high predictive efficacy and clinical application value of the model. Conclusions The number of red blood cell transfusions, use of PS 2 times or more, and preoperative fundus hemorrhage are independent risk factors for ROP reactivate. The nomogram model constructed based on these factors has high predictive efficacy and clinical application value.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Intravitreal Anti-Vascular Endothelial Growth Factor Treatment and the Risk of Thromboembolism
    Schlenker, Matthew B.
    Thiruchelvam, Deva
    Redelmeier, Donald A.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2015, 160 (03) : 569 - 580
  • [32] Is Anti-Vascular Growth Factor Therapy for Retinopathy of Prematurity Associated With Pulmonary Hypertension?
    Nitkin, Christopher R.
    Richardson, Troy
    Lewis, Tamorah
    JAMA OPHTHALMOLOGY, 2023, 141 (04) : 407 - 408
  • [33] The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity—a current review
    Shing Chuen Chow
    Pun Yuet Lam
    Wai Ching Lam
    Nicholas Siu Kay Fung
    Eye, 2022, 36 : 1532 - 1545
  • [34] Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF)
    Tsai, Andrew SH.
    Chou, Hung-Da
    Ling, Xiao Chun
    Al-Khaled, Tala
    Valikodath, Nita
    Cole, Emily
    Yap, Vivien L.
    Chiang, Michael F.
    Chan, R. V. Paul
    Wu, Wei-Chi
    PROGRESS IN RETINAL AND EYE RESEARCH, 2022, 88
  • [35] Aggravation of retinal hard exudates after intravitreal anti-vascular endothelial growth factor therapy for cystoid macular edema and the risk factors: a retrospective study
    Rui Shi
    Zhonglan Guo
    Xiangxiang Yang
    Xuanyi Che
    BMC Ophthalmology, 22
  • [36] Aggravation of retinal hard exudates after intravitreal anti-vascular endothelial growth factor therapy for cystoid macular edema and the risk factors: a retrospective study
    Shi, Rui
    Guo, Zhonglan
    Yang, Xiangxiang
    Che, Xuanyi
    BMC OPHTHALMOLOGY, 2022, 22 (01)
  • [37] Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: A survey among the members of Indian Retinopathy of Prematurity Society
    Gangwe, Anil
    Agrawal, Deepanshu
    Vinekar, Anand
    Azad, Raj, V
    Parchand, Swapnil M.
    Agrawal, Deepshikha
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2021, 69 (08) : 2158 - 2163
  • [38] Systemic immunosuppression and risk of endophthalmitis after intravitreal anti-vascular endothelial growth factor injections
    Kim, Julie Sun
    Patel, Samir N.
    Storey, Philip P.
    Obeid, Anthony
    Hsu, Jason
    Garg, Sunir J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [39] Systemic Immunosuppression and Risk of Endophthalmitis After Intravitreal Anti-Vascular Endothelial Growth Factor Injections
    Patel, Samir N.
    Storey, Philip P.
    Kim, Julie S.
    Obeid, Anthony
    Pancholy, Maitri
    Hsu, Jason
    Garg, Sunir J.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2021, 52 (07): : S17 - S22
  • [40] Timing of laser following intravitreal anti-vascular endothelial growth factor injections for aggressive posterior zone 1 retinopathy of prematurity
    Vinekar, Anand
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2021, 69 (08) : 1988 - 1989